KR102493174B1 - 고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아 - Google Patents

고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아 Download PDF

Info

Publication number
KR102493174B1
KR102493174B1 KR1020177018338A KR20177018338A KR102493174B1 KR 102493174 B1 KR102493174 B1 KR 102493174B1 KR 1020177018338 A KR1020177018338 A KR 1020177018338A KR 20177018338 A KR20177018338 A KR 20177018338A KR 102493174 B1 KR102493174 B1 KR 102493174B1
Authority
KR
South Korea
Prior art keywords
delete delete
arginine
promoter
gene
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177018338A
Other languages
English (en)
Korean (ko)
Other versions
KR20170097078A (ko
Inventor
딘 팔브
빈센트 엠. 이사벨라
조나단 더블유. 코툴라
폴 에프. 밀러
Original Assignee
신로직 오퍼레이팅 컴퍼니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 filed Critical 신로직 오퍼레이팅 컴퍼니, 인코포레이티드
Publication of KR20170097078A publication Critical patent/KR20170097078A/ko
Application granted granted Critical
Publication of KR102493174B1 publication Critical patent/KR102493174B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01001—Amino-acid N-acetyltransferase (2.3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
KR1020177018338A 2014-12-05 2015-12-04 고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아 Active KR102493174B1 (ko)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201462087854P 2014-12-05 2014-12-05
US62/087,854 2014-12-05
US201562103513P 2015-01-14 2015-01-14
US62/103,513 2015-01-14
US201562150508P 2015-04-21 2015-04-21
US62/150,508 2015-04-21
US201562173710P 2015-06-10 2015-06-10
US201562173706P 2015-06-10 2015-06-10
US62/173,706 2015-06-10
US62/173,710 2015-06-10
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562184811P 2015-06-25 2015-06-25
US62/184,811 2015-06-25
US201562256041P 2015-11-16 2015-11-16
US201562256039P 2015-11-16 2015-11-16
US62/256,039 2015-11-16
US62/256,041 2015-11-16
US201562263329P 2015-12-04 2015-12-04
PCT/US2015/064140 WO2016090343A1 (en) 2014-12-05 2015-12-04 Bacteria engineered to treat diseases associated with hyperammonemia
US62/263,329 2015-12-04

Publications (2)

Publication Number Publication Date
KR20170097078A KR20170097078A (ko) 2017-08-25
KR102493174B1 true KR102493174B1 (ko) 2023-01-27

Family

ID=55022714

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018338A Active KR102493174B1 (ko) 2014-12-05 2015-12-04 고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아

Country Status (10)

Country Link
US (1) US9487764B2 (https=)
JP (1) JP6768689B2 (https=)
KR (1) KR102493174B1 (https=)
AU (1) AU2015357549B2 (https=)
BR (1) BR112017011923A2 (https=)
CA (1) CA2969724A1 (https=)
IL (2) IL252627B (https=)
MX (2) MX383245B (https=)
SG (2) SG11201704543XA (https=)
WO (1) WO2016090343A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
SG11201704543XA (en) * 2014-12-05 2017-07-28 Synlogic Inc Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
ES2881384T3 (es) * 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
EP4302824A3 (en) 2016-04-20 2024-03-20 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
BR112019013863A2 (pt) 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. Micro-organismos programados para produzir moduladores imunes e terapêuticos anticâncer em células tumorais
US20200056145A1 (en) * 2017-04-17 2020-02-20 The Regents Of The University Of California Engineered commensal bacteria and methods of use
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US20200113950A1 (en) * 2017-06-30 2020-04-16 The Rockefeller University Human microbiota derived N-acyl amides for the treatment of human disease
JP2020527025A (ja) * 2017-07-12 2020-09-03 シンロジック オペレーティング カンパニー インコーポレイテッド 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
AU2018379996A1 (en) * 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
JP2021525760A (ja) 2018-06-02 2021-09-27 シンロジック オペレーティング カンパニー インコーポレイテッド 肝疾患を処置するように操作された細菌
EP3841127A2 (en) 2018-08-21 2021-06-30 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for reducing ammonia levels
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
CA3118909A1 (en) 2018-11-08 2020-05-14 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
WO2020237246A1 (en) * 2019-05-23 2020-11-26 University Of Maryland, Baltimore Live attenuated non-transmissible vaccines
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
US12290540B2 (en) 2019-11-29 2025-05-06 Jinis Co., Ltd Strain having ability to lower blood ammonia levels and composition comprising same for neuronal protection
CN112924607A (zh) * 2019-12-05 2021-06-08 湖北远大生物技术有限公司 一种同时检测酶促反应液中α-酮戊二酸和L-谷氨酸的方法
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
EP4256039A2 (en) 2020-12-02 2023-10-11 Synlogic Operating Company, Inc. Engineered microorganisms
JP2024501870A (ja) * 2020-12-30 2024-01-16 エリゴ・バイオサイエンス 拡散を最小限に抑えたｄｎａペイロードの送達による宿主のマイクロバイオーム調節
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
KR102853096B1 (ko) * 2022-03-18 2025-09-02 씨제이제일제당 주식회사 카르바모일 인산 합성효소의 활성이 약화된 l-아미노산을 생산하는 미생물 및 이를 이용한 l-아미노산 생산 방법
CN115960807A (zh) * 2022-11-29 2023-04-14 深圳先进技术研究院 一种厌氧高产l-精氨酸工程菌及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
AU3108400A (en) 1998-12-02 2000-06-19 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP4682454B2 (ja) * 2000-06-28 2011-05-11 味の素株式会社 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法
DE10101793A1 (de) * 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
DE602005020165D1 (de) * 2004-09-28 2010-05-06 Kyowa Hakko Bio Co Ltd Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
SG11201704543XA (en) * 2014-12-05 2017-07-28 Synlogic Inc Bacteria engineered to treat diseases associated with hyperammonemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY. 1998, vol. 64, no. 5, pages 1805-1811.
J. BIOL. CHEM. 2008, vol. 283, no. 10, pages 6347-6358.
MOLECULAR MICROBIOLOGY. 1994, vol. 13, no. 4, pages 599-608.

Also Published As

Publication number Publication date
MX2017007148A (es) 2017-10-11
US20160177274A1 (en) 2016-06-23
JP6768689B2 (ja) 2020-10-14
WO2016090343A9 (en) 2016-09-09
JP2018504919A (ja) 2018-02-22
AU2015357549B2 (en) 2022-03-24
AU2015357549A1 (en) 2017-06-29
US9487764B2 (en) 2016-11-08
CA2969724A1 (en) 2016-06-09
MX383245B (es) 2025-03-13
BR112017011923A2 (pt) 2018-02-27
WO2016090343A1 (en) 2016-06-09
KR20170097078A (ko) 2017-08-25
SG10202010444UA (en) 2020-11-27
IL252627B (en) 2020-11-30
IL252627A0 (en) 2017-07-31
MX2021006581A (es) 2021-07-15
IL278150A (en) 2020-11-30
SG11201704543XA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
KR102493174B1 (ko) 고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아
KR101417146B1 (ko) 이소프레노이드의 생산 방법
AU2018350754B2 (en) Fermentative production of N-acetylneuraminic acid
KR102021914B1 (ko) 아세틸-코엔자임 a로부터 유래되는 이소프레노이드의 제조 방법
AU2016276973B2 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
KR102700050B1 (ko) 조작된 내수송/외수송을 가진 미생물 숙주에서 모유 올리고당류의 생산
CN101437953B (zh) 用于改变含油生物的多不饱和脂肪酸和油含量的二酰基甘油酰基转移酶
AU2016356684B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
KR20220109395A (ko) 실로시빈 및 중간체 또는 부산물의 생산 방법
KR20090018978A (ko) 생물 유기 화합물을 제조하기 위한 장치
CN101617040A (zh) △17去饱和酶及其在制备多不饱和脂肪酸中的用途
BRPI0619325A2 (pt) células hospedeiras microbianas recombinantes, métodos para produção de isobutanol e meio de fermentação que contém isobutanol
KR20140131939A (ko) 유전자 조작된 미생물로부터 뮤콘산의 생산
CA2509472A1 (en) Increasing carotenoid production in bacteria via chromosomal integration
KR20190003939A (ko) 유전자 조작된 미생물로부터 개선된 뮤콘산 생산
Tokunaga et al. Isolation and characterization of an Escherichia coli clone overproducing prolipoprotein signal peptidase.
TW202241475A (zh) 用於預防和／或治療宿醉和肝病的基因改造細菌
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
KR20010053141A (ko) 프로피오니박테리움 벡터
KR20160006030A (ko) CoA 아실화 알데히드 데히드게나제 활성이 증가된 신규한 아크릴산 생성 경로를 갖는 미생물 및 이를 이용한 아크릴산 생산 방법
CN114480385A (zh) 基于来自耐酸酵母的基因的合成启动子
US20040209365A1 (en) Parallel chromosomal stacking of traits in bacteria
CN115960807A (zh) 一种厌氧高产l-精氨酸工程菌及其制备方法和应用
CN114250239A (zh) 甘氨酸核糖开关基因调控线路的构建方法及应用
CN113846071B (zh) 一种酶活提高的丙氨酸-乙醛酸转氨酶突变体及应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220529

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration